MorphoSys AG (Frankfurt: MOR; Prime Standard Segment, TecDAX) and Roche today announced a collaboration to develop new therapeutic antibodies in oncology. Expanding on a September 2000 relationship in Alzheimer’s disease, Roche will elect new target molecules against which MorphoSys will generate antibodies using its proprietary HuCAL GOLD® technology.
